Is Quantitative Histologic Examination Useful to Predict Nonorgan-Confined Prostate Cancer When Saturation Biopsy Is Performed?

Urology

Volumn 72, Issue 6, 2008, Pages 1198-1202

  Pepe, P ^a   Fraggetta, F ^a   Galia, A ^a   Grasso, G ^a   Piccolo, S ^b   Aragona, F ^a  

^a CANNIZZARO HOSPITAL   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; SENSITIVITY AND SPECIFICITY;

AGED; BIOPSY; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UROLOGY;

EID: 56449113982     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.05.045     Document Type: Article

References (28)

1. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of PSA, clinical stage and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 277 (1997) 1445-1451
2. Walsh P.C., DeWeese T.L., and Eisenberger M.A. Localized prostate cancer. N Engl J Med 357 (2007) 2696-2705
3. Kattan M.W., Stapleton A.M., Wheeler T.M., et al. Evaluation of a nomogram used to predict pathologic stage of clinically localized prostate carcinoma. Cancer 79 (1997) 528-537
4. Algaba F., Arce Y., Oliver A., et al. Prognostic parameters other than Gleason score for the daily evaluation of prostate cancer in needle biopsy. Eur Urol 48 (2005) 566-571
5. Poulos C.K., Daggy J.K., and Cheng L. Prostate needle biopsies: Multiple variables are predictive of final tumor volume in radical prostatectomy. Cancer 101 (2004) 527-532
6. D'Amico A.V., Renshaw A.A., Cote K., et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favourable intermediate-risk disease. J Clin Oncol 22 (2004) 3726-3732
7. Freedland S.J., Aronson W.J., Csathy G.S., et al. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: Results from the search database. Urology 61 (2003) 742-747
8. Grossklaus D.J., Coffey C.S., Shappell S.B., et al. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol 167 (2002) 2032-2035
9. Naya Y., Slaton J.W., Troncoso P., et al. Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension. J Urol 171 (2004) 1093-1097
10. Gancarczyk K.J., Wu H., McLeod D.G., et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: The center for prostate disease research nomograms. Urology 61 (2003) 589-595
11. Suekane S., Noguchi M., Nakashima O., et al. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy. Int J Urol 14 (2007) 713-718
12. Pepe P., Galia A., Fraggetta F., et al. Prediction by quantitative histology of pathological stage in prostate cancer. Eur J Surg Oncol 31 (2005) 309-313
13. Walz J., Graefen M., Chun F.K., et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 50 (2006) 498-505
14. Sajadi K.P., Kim T., Terris M.K., et al. High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates. Urology 70 (2007) 691-695
15. Pepe P., and Aragona F. Saturation prostate needle biopsy and prostate cancer at initial and repeat evaluation. Urology 70 (2007) 1131-1135
16. Aragona F., Pepe P., Motta M., et al. Incidence of prostate cancer in Sicily: Results of a multicenter case-findings protocol. Eur Urol 47 (2005) 569-574
17. Bostwick D.G., Grignon D.J., Hammond M.E., et al. Prognostic factors in prostate cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124 (2000) 995-1000
18. Veltri R.W., Miller M.C., Partin A.W., et al. Prediction of prostate carcinoma stage by quantitative biopsy pathology. Cancer 91 (2001) 2322-2328
19. Felix K., Chun H., Karakiewicz P.I., et al. Prostate cancer nomograms: An update. Eur Urol 50 (2006) 914-926
20. Freedland S.J., Terris M.K., Csathy G.S., et al., Search Database Study Group. Preoperative model for predicting PSA recurrence after radical prostatectomy using percent of biopsy with cancer, biopsy Gleason grade and serum PSA. J Urol 171 (2004) 2215-2220
21. Nelson C.P., Rubin M.A., Strawderman M., et al. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology 59 (2002) 740-745
22. Freedland S.J., Csathy G.S., Dorey F., et al. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than PSA or Gleason score. J Urol 167 (2002) 516-520
23. Nelson C.P., Dunn R.L., Wei J.T., et al. Contemporary preoperative parameters predict cancer-free after radical prostatectomy: A tool to facilitate treatment decisions. Urol Oncol 21 (2003) 213-218
24. Gao X., Mohideen N., Flanigan R.C., et al. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: Implications for treatment selection. J Urol 164 (2000) 1982-1986
25. Bismar T.A., Lewis Jr. J.S., Vollmer R.T., et al. Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population. Am J Surg Pathol 27 (2003) 432-440
26. Joniau S., Hsu C.Y., Lerut E., et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 51 (2007) 388-394
27. Haese A., Chaudhari M., Miller M.C., et al. Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate cancer: A multiinstitutional validation study. Cancer 97 (2003) 969-978
28. Epstein J.L., Walsh P.C., and Carmichael M. Pathological and clinical findings to predict tumor extent of non palpable (stage T1c) prostate cancer. JAMA 271 (1994) 368-374